prostate apoptosis response protein PAR-4 (2-7) [Homo sapiens]
(Synonyms: H2N-Ala-Thr-Gly-Gly-Tyr-Arg-OH ) 目录号 : GP10002
Transcriptional repressor
![prostate apoptosis response protein PAR-4 (2-7) [Homo sapiens] Chemical Structure](/media/struct/GP1/GP10002.png "prostate apoptosis response protein PAR-4 (2-7) [Homo sapiens] Chemical Structure")
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
prostate apoptosis response protein PAR-4 (2-7) [Homo sapiens], (C26H41N9O9), a peptide with the sequence H2N-Ala-Thr-Gly-Gly-Tyr-Arg-OH, MW= 623.66. Prostate apoptosis response-4 (Par-4), is a human gene coding for a tumor-suppressor protein that induces apoptosis in cancer cells, but not in normal cells.The tumor suppressor PAR-4 represses and activates transcription. The protein encoded by this gene is a PAR-4-interacting protein that itself functions as a transcriptional repressor. It contains a putative leucine zipper domain which interacts with the zinc finger DNA binding domain of PAR-4. This protein is specifically upregulated during apoptosis of prostate cells1.The active domain of the Par-4 protein has been found to confer cancer resistance in transgenic mice without compromising normal viability or aging, and may have therapeutic significance2.
References:
1. Johnstone, R W; See R H, Sells S F, Wang J, Muthukkumar S, Englert C, Haber D A, Licht J D, Sugrue S P, Roberts T, Rangnekar V M, Shi Y (Dec. 1996). "A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1". Mol. Cell. Biol. (UNITED STATES) 16 (12): 6945-56.
2. Zhao Y, Burikhanov R, Qiu S, Lele SM, JenningsCD, Bondada S, Spear B, Rangnekar VM (2007). "Cancer resistance in transgenic mice expressing the SAC module of Par-4". Cancer Res. 67 (19): 9276-85.
| Cas No. | SDF | ||
| 别名 | H2N-Ala-Thr-Gly-Gly-Tyr-Arg-OH | ||
| Canonical SMILES | CC(C(NC(C(O)C)C(NCC(NCC(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)N | ||
| 分子式 | C26H41N9O9 | 分子量 | 623.66 |
| 溶解度 | ≥ 62.3mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6034 mL | 8.0172 mL | 16.0344 mL |
| 5 mM | 0.3207 mL | 1.6034 mL | 3.2069 mL |
| 10 mM | 0.1603 mL | 0.8017 mL | 1.6034 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。